Welcome to our dedicated page for Sarepta Therapeutics news (Ticker: SRPT), a resource for investors and traders seeking the latest updates and insights on Sarepta Therapeutics stock.
Sarepta Therapeutics, Inc. develops and commercializes precision genetic medicines for rare diseases, with a central focus on Duchenne muscular dystrophy and other neuromuscular conditions. Company news commonly covers product revenue and commercialization trends for ELEVIDYS and PMO therapies, including AMONDYS 45, VYONDYS 53 and EXONDYS 51.
Updates also address FDA interactions for Duchenne therapies, clinical and biomarker data from the siRNA pipeline, and programs such as SRP-1001 for FSHD1 and SRP-1003 for DM1. Other recurring announcements include quarterly financial results, Nasdaq inducement equity grants, and patient-community initiatives tied to Duchenne muscular dystrophy.
Sarepta Therapeutics (NASDAQ:SRPT) announced the commercial launch of ELEVIDYS in Japan on February 24, 2026, via Chugai after National Health Insurance reimbursement and MHLW conditional, time-limited approval (May 2025).
ELEVIDYS is available for ambulatory Duchenne patients aged 3 to less than 8 years with deletions in exon 8 and/or exon 9 and negative anti-AAVrh74 status; the first Japan sale triggers a $40 million milestone payment to Sarepta.
Sarepta Therapeutics (NASDAQ:SRPT) said senior management will appear in a fireside chat at the TD Cowen 46th Annual Health Care Conference in Boston on March 3, 2026 at 1:50 p.m. ET. The presentation will be webcast live via the company's investor relations site and archived for 90 days.
Investors are advised to connect several minutes early to allow time for any required software downloads.
Sarepta Therapeutics (NASDAQ:SRPT) will report fourth-quarter and full-year 2025 financial results after the Nasdaq close on Wednesday, Feb. 25, 2026.
A conference call and live webcast will follow at 4:30 p.m. ET; a replay will be archived on the company's investor site for one year. Phone participants must register to receive dial-in details and a personal PIN.
Sarepta (NASDAQ:SRPT) announced Medsafe approval of the clinical trial application for SRP-1005, enabling the Phase 1 INSIGHTT study to begin. The first-in-human, multi-center, dose-escalation trial will enroll ~24 participants and is expected to start in Q2 2026.
SRP-1005 is an siRNA designed with a TfR1 monovalent fAb delivery approach for subcutaneous dosing to target deep brain regions in Huntington’s disease.
Sarepta (NASDAQ:SRPT) reported positive topline three-year results from Part 1 of EMBARK showing durable, statistically significant motor benefit for ELEVIDYS (delandistrogene moxeparvovec-rokl) in ambulatory Duchenne patients treated at ages 4–7 and followed to a mean age of ~9. At Year 3 (n=52 treated), mean NSAA remained above baseline (+4.39 LSM vs external control, p=0.0002), with TTR and 10MWR showing sustained improvement versus a propensity-weighted external control (TTR LSM difference -6.05s; 10MWR -2.70s, p=0.0039) and ~70% or greater slowing of decline on timed tests. No new treatment-related safety signals were observed; analysis and publications are ongoing.
Sarepta Therapeutics (NASDAQ:SRPT) will present 3-year topline functional results from Part 1 of EMBARK (Study 9001-301) on Jan. 26, 2026 at 8:30 AM ET. EMBARK is a global, randomized, placebo-controlled Phase 3 study evaluating ELEVIDYS (delandistrogene moxeparvovec-rokl) in ambulatory individuals with Duchenne muscular dystrophy who were aged four to seven at treatment.
The company will host a live webcast and conference call under its investor relations site and will archive a replay for one year. Phone participants must register online to receive dial-in details and a personal PIN via auto-generated email.
Sarepta (NASDAQ:SRPT) reported preliminary, unaudited Q4 2025 net product revenue of $369.6M and full-year 2025 net product revenue of $1.86B. ELEVIDYS revenue was $110.4M in Q4 and $898.7M for 2025; PMO revenues were $259.2M in Q4 and $965.6M for 2025. Preliminary cash, cash equivalents, restricted cash and investments totaled approximately $953.8M at Dec 31, 2025. The company reconfirmed a yearly ELEVIDYS sales floor of $500.0M but will not provide detailed 2026 guidance until initiatives are evaluated. Results are preliminary and subject to adjustment; final 2025 results expected in late February 2026.
Sarepta Therapeutics (NASDAQ:SRPT) submitted a clinical trial application to Medsafe for SRP-1005 (INSIGHTT), an investigational subcutaneous siRNA therapy for Huntington’s disease.
Pending approval, the first-in-human Phase 1 INSIGHTT study is expected to start in Q2 2026 and will enroll ~24 participants in a multi-center, dose-escalation safety and tolerability trial. Preclinical data showed protein knockdown in deep brain regions including the putamen and caudate.
Sarepta Therapeutics (NASDAQ:SRPT) said senior management will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2026 at 12:00 p.m. ET / 9:00 a.m. PT, with a Q&A starting at 12:20 p.m. ET / 9:20 a.m. PT.
The presentation will be webcast live via the Events & Presentations section of Sarepta’s investor website and will be archived for 90 days. Attendees are advised to connect to the webcast several minutes early to allow time for any required software download.
Sarepta describes its mission as engineering precision genetic medicine for rare diseases, with leadership in Duchenne muscular dystrophy and programs across muscle, central nervous system, and cardiac diseases.
Sarepta Therapeutics (NASDAQ:SRPT) granted equity awards on Dec. 31, 2025 as material inducements to employment for 10 individuals hired in Q4 2025. The awards, approved under Sarepta’s 2024 Employment Commencement Incentive Plan and in accordance with Nasdaq Listing Rule 5635(c)(4), total 55,118 restricted stock units (RSUs) granted in the aggregate. The RSUs vest 25% annually on each anniversary of the grant date and will be fully vested on the fourth anniversary, subject to continued employment. No stock options were granted to these employees.